Eli Lilly Seeks FDA Approval for Cymbalta ASSOCIATED PRESS INDIANAPOLIS (AP) - Drug Eli Lilly and Co. said Friday that it has filed with the Food and Drug Administration to have its antidepressant Cymbalta approved for the treatment of generalized anxiety disorder. The company said that it will use data from two clinical trials to support the application. Generalized anxiety disorder is a condition lasting for at least six months characterized by exaggerated worry or chronic anxiety and irritability, and may include physical symptoms like muscle tension, restlessness and insomnia. Cymbalta was approved by the FDA in August 2004 for the treatment of major depression, and in September 2004 for the treatments of diabetic nerve pain. Other antidepressants approved for generalized anxiety disorder include Forest Labs' Lexapro, Wyeth's Effexor, and GlaxoSmithKline's Paxil.